Related Experiment Video
Updated: Mar 14, 2026
Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention
Lotte Kaasenbrood1, S Matthijs Boekholdt1, Yolanda van der Graaf1
1From Department of Vascular Medicine (L.K., J.W., F.L.J.V.), Julius Centre for Health Sciences and Primary Care (Y.v.d.G.), Department of Cardiology (M.J.M.C.), Department of Neurology (L.J.K.), and Department of Vascular Surgery (G.J.d.B.), University Medical Centre Utrecht, the Netherlands; Departments of Cardiology (S.M.B., R.J.G.P.) and Vascular Medicine (J.J.P.K.), Academic Medical Centre, Amsterdam, the Netherlands; School of Public Health, Imperial College London, United Kingdom (K.K.R.); Department of Neurology and Stroke Center, Bichat University Hospital, Paris, France (P.A.); and SUNY Health Science Center at Brooklyn, New York, NY (J.C.L.).
Background:
Among patients with clinically manifest vascular disease, the risk of recurrent vascular events is likely to vary. We assessed the distribution of estimated 10-year risk of recurrent vascular events in a secondary prevention population. We also estimated the potential risk reduction and residual risk that can be achieved if patients reach guideline-recommended risk factor targets.
Methods:
The SMART score (Second Manifestations of Arterial Disease) for 10-year risk of myocardial infarction, stroke, or vascular death was applied to 6904 patients with vascular disease. The risk score was externally validated in 18 436 patients with various manifestations of vascular disease from the TNT (Treating to New Targets), IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering), SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels), and CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events) trials. The residual risk at guideline-recommended targets was estimated by applying relative risk reductions from meta-analyses to the estimated risk for targets for systolic blood pressure, low-density lipoprotein cholesterol, smoking, physical activity, and use of antithrombotic agents.
Results:
The external performance of the SMART risk score was reasonable, apart from overestimation of risk in patients with 10-year risk >40%. In patients with various manifestations of vascular disease, median 10-year risk of a recurrent major vascular event was 17% (interquartile range, 11%-28%), varying from <10% in 18% to >30% in 22% of the patients. If risk factors were at guideline-recommended targets, the residual 10-year risk would be <10% in 47% and >30% in 9% of the patients (median, 11%; interquartile range, 7%-17%).
Conclusions:
Among patients with vascular disease, there is very substantial variation in estimated 10-year risk of recurrent vascular events. If all modifiable risk factors were at guideline-recommended targets, half of the patients would have a 10-year risk <10%. These data suggest that even with optimal treatment, many patients with vascular disease will remain at >20% and even >30% 10-year risk, clearly delineating an area of substantial unmet medical need.
Related Concept Videos
01:12Relative Risk
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:26Coronary Artery Disease IV: Preventive Measures
01:20Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:29Venous Thrombosis III: Interprofessional Care